Astellas Pharma Inc. has had a substantial presence in recent news, with the majority indicating positive developments. The company's oncology sphere continues to see progress with collaborations such as Vir Biotechnology for an advanced PSMA-targeting T-Cell Engager for prostate cancer treatment. Astellas claims victories in ongoing patent battles including its bladder medication against Ascent’s Myrbetriq and Lupin, settling the latter for $90 million. Pfizer and Astellas also deliver positive outcomes in multiple Phase 3 trials, lending further strength to their pharmaceutical partnership. Despite facing headwinds with oncology pipeline setbacks, Astellas enters a $1.7 billion global collaboration with Vir Biotechnology to continue pushing its PRO-XTEN. Furthermore, the biotech giant will present groundbreaking findings across its portfolio at the future ESMO 2025. Astellas is garnering interest with trading volumes seeing large increases and their stock hitting significant overall growth, despite the occasional dips. The company announced strategic partnerships with various companies to enhance global clinical development using AI platforms, and is also moving its datacenters to Azure, further showing its innovative progression.
Astellas Pharma Inc. News Analytics from Wed, 31 May 2017 01:19:45 GMT to Fri, 13 Mar 2026 21:56:55 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor 5
